Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc. (AYLA) Stock Overview
Explore Ayala Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
AYLA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Ayala Pharmaceuticals, Inc. (AYLA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.24.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.22 and a market capitalization of 0. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Roni Mamluk
35
4 Oppenheimer Street, Rehovot
2020